𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Liver cirrhosis and portal hypertension in cystic fibrosis

✍ Scribed by Yoram Bujanover; Ori Efrati; Asher Barak; Jacob Yahav

Book ID
118565484
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
108 KB
Volume
36
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cystic fibrosisβ€”cirrhosis, portal hypert
Cystic fibrosisβ€”cirrhosis, portal hypertension, and liver biopsy: Reply
✍ Peter J. Lewindon; Grant A. Ramm πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 632 KB

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.

Portal hypertension in cystic fibrosis
Portal hypertension in cystic fibrosis
✍ Kenneth R.T. Tyson; Samuel R. Schuster; Harry Shwachman πŸ“‚ Article πŸ“… 1968 πŸ› Elsevier Science 🌐 English βš– 539 KB
Noncirrhotic presinusoidal portal hypert
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis–associated liver disease
✍ Peter Witters; Louis Libbrecht; Tania Roskams; Kris De Boeck; Lieven Dupont; Mar πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 632 KB

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.